TGTX Earnings
Latest Revenue259.9M
Latest Net Income55.5M
| Period | EPS | Revenue | Net Income | Rev YoY | EPS YoY |
|---|
| Q3 2026 | $0.39 | 259.9M | 55.5M | +60.7% | -85.5% |
| Q2 2026 | $0.05 | 240.3M | 7.8M | +70.3% | -73.7% |
| Q1 2026 | $0.14 | 204.9M | 19.8M | +69.6% | +366.7% |
| Q4 2025 | $0.17 | 192.6M | 23.0M | +78.0% | +6.3% |
| Q3 2025 | $2.69 | 161.7M | 390.9M | +92.8% | +8,866.7% |
| Q2 2025 | $0.19 | 141.1M | 28.2M | +92.1% | +280.0% |
| Q1 2025 | $0.03 | 120.9M | 5.1M | +90.4% | +142.9% |
| Q4 2024 | $0.16 | 108.2M | 23.3M | +146.0% | +260.0% |
| Q3 2024 | $0.03 | 83.9M | 3.9M | — | — |
| Q2 2024 | $0.05 | 73.5M | 6.9M | — | — |
| Q1 2024 | -$0.07 | 63.5M | -10707000 | — | — |
| Q4 2023 | -$0.10 | 44.0M | -14416000 | — | — |
TG Therapeutics (TGTX) — Earnings